Latest Conference Coverage

Cultural Shifts in Adapting to the New Criteria for Multiple Sclerosis Diagnosis: Marcello Moccia, MD, PhD

The assistant professor at the University of Naples discussed how implementation of new diagnostic criteria for multiple sclerosis will involve practical adjustments in imaging and diagnostic techniques as well as cultural changes in clinical practice. [WATCH TIME: 4 minutes]

Horizon Study Update for MSA Drug ION464, OnaboutlinumtoxinA to be Tested in Essential Tremor, Challenges With Ketogenic-Mediterranean Diets in PD

Neurology News Network. for the week ending October 5, 2024. [WATCH TIME: 4 minutes]

Valbenazine Shows Sustained Treatment Effect on Huntington’s Chorea in KINECT-HD2 Open-Label Data

Over a 12-month period, patients showed sustained improvements in disease progression through valbenazine, regardless of concomitant antipsychotic treatment.

Episode 125: Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 27 minutes]

Understanding Radiologically Isolated Syndrome as Either Presymptomatic MS or an Independent Condition: Mikael Cohen, MD

The neurologist at the University Hospital Center of Nice discussed whether radiologically isolated syndrome represents a pre-symptomatic phase of multiple sclerosis based on a hot topic session held at the 2024 ECTRIMS Congress. [WATCH TIME: 4 minutes]

Promising Effects of Vidofludimus Calcium by Age and Disability in Progressive MS: Robert J. Fox, MD; Andreas Muehler, MD, MBA

A duo of experts talked about a positive phase 2 trial of vidofludimus calcium, demonstrating reductions in serum neurofilament light levels and potentially slowing brain atrophy in patients with progressive multiple sclerosis. [WATCH TIME: 4 minutes]

NORAPS Phase 2 Trial to Test Noradrenaline Reuptake Inhibitor Atomoxetine in PSP Apathy and Impulsivity

This trial aims to explore the role of the noradrenergic system in behavioral and cognitive outcomes and could lead to new therapeutic strategies for managing PSP.

Continued Progress in Phase 1 Study of Antisense Oligonucleotide ION464 in MSA

ION464 is designed to inhibit the production of the alpha-synuclein protein, aiming to reduce the accumulation of this protein in the brain, which is believed to be a key factor driving neurodegeneration in MSA and Parkinson disease.

Potential Promise Behind ATH434 for Multiple System Atrophy: Daniel Claassen, MD, MS

The director of the Huntington’s Disease Clinic at Vanderbilt University Medical Center gave commentary on the unique development of ATH434, its ability to target iron accumulation, and how it may slow disease progression in multiple system atrophy. [WATCH TIME: 3 minutes]

NeuroVoices: Lucia Ricciardi, MD, PhD, on Addressing Neuropsychiatric Symptom Management in Parkinson Disease

The consultant neurologist and senior lecturer at St. Georges Hospital in London, provided commentary on the diagnosis, management, and future research around neuropsychiatric symptoms of Parkinson disease.

Patients Highly Recommend Continuous Subcutaneous Apomorphine Infusion for Parkinson Disease, Survey Says

A recent survey showed that patients with Parkinson disease quickly adapted to using continuous subcutaneous apomorphine infusion therapy, with high amount of recommending the device to others.

Extended-Release Amantadine Shows Reduction in Dyskinesia Severity for Parkinson Disease

Amantadine extended-release capsules, approved for levodopa-related dyskinesia and OFF episodes in Parkinson disease, offer high amantadine concentrations that peak in the time of first morning levodopa dose.

Positive 24-Month Data of Cell Therapy Bemdaneprocel in Parkinson Disease: Amit Rakhit, MD

The chief medical officer and chief development officer at BlueRock Therapeutics provided perspective on newly presented data investigating a cell therapy for patients with Parkinson disease. [WATCH TIME: 4 minutes]

Mechanism Behind Ulixacaltamide to Treat Essential Tremor: Marcio Souza

The president and chief executive officer at Praxis Precision Medicine provided clinical insight on the promising build of ulixacaltamide, an investigational, selective agent in development for essential tremor. [WATCH TIME: 3 minutes]

Randomized Controlled ELATE Study to Test OnabotulinumtoxinA in Upper Limb Essential Tremor

ELATE, a multicenter, randomized, double-blind, placebo-controlled trial, aims to address the limitations of current oral therapies by exploring a targeted, localized treatment option.

Nocturnal and Morning Akinesia Still Prevalent After Nighttime Add-On Parkinson Medications

In a post hoc analysis of the COSMOS study, 24-hour LCIG infusion led to a reduction in nocturnal and morning akinesia, though many patients continued to rely on nighttime add-on medications.

Potential of Device-Assisted Therapy for Advanced-Stage Parkinson Disease: David Devos, MD, PhD

The neuropharmacologist at the University of Lille, in France, provided commentary on promising results from the phase 1/2 DIVE-I trial assessing the safety and efficacy of a device-assisted therapy in Parkinson disease. [WATCH TIME: 6 minutes]

Study Data Suggests Difficulties With Mediterranean-Ketogenic Dietary Intervention in Parkinson Disease

While participants responded positively to nutritional guidance and the Mediterranean diet, they expressed negative views on the ketogenic diet due to its restrictive nature, social impracticality, and gastrointestinal side effects of MCT oil.

MDS Poster Highlights Long-Term Sustained Efficacy of Adjunctive Continuous Subcutaneous Apomorphine Infusion

Patients reported increased good ON time and improved confidence in daily activities while experiencing a lower treatment burden compared to their previous medication regimens.

A-Synuclein Antibody Lu AF82422 Shows Disease-Modifying Potential in Phase 2 AMULET Trial of MSA

Lu AF84222 was considered well tolerated, with greater treatment effects observed in a subgroup of patients with less impaired multiple system atrophy.

Continued Progress in Path to Prevention Therapeutics Platform Trial of Stage 2B Neuronal Alpha-Synuclein Disease

Path to Prevention is a platform, phase 2 trial that will investigate the safety and efficacy of investigational interventions in patients neuronal α-synuclein disease stage 2B.

Severe Cholinergic Denervation Observed in Parkinson Disease Relative to Progressive Supranuclear Palsy-Parkinsonism

Findings from a new study presented at MDS 2024 suggest that variations in cholinergic denervation patterns may hold promise for differentiating Parkinson disease and progressive supranuclear palsy with parkinsonism.

Parkinson Disease Cognition Improved in Phase 2 Study of TAK-071

Despite showing no differences vs placebo on the primary end point of gait parameters, TAK-071-treated patients demonstrated significant improvements in global cognition score.

Perspectives on Updated McDonald Criteria to Transform MS Diagnosis: Wallace Brownlee, MBChB, PhD, FRACP

The consultant neurologist at Queen's Square MS Center in London gave his clinical viewpoint on the newest revision of the McDonald criteria for diagnosing patients with multiple sclerosis. [WATCH TIME: 3 minutes]

Addressing the Neurologist Shortage Through Career Opportunities and Supporting Early Investigators: Claire Henchcliffe, MD, DPhil, FANA; Ali Ezzati, MD

A pair of neurologists from the University of California, Irvine, detailed some of the training and career focuses of large federal agencies in effort to address the shortage of neurologists. [WATCH TIME: 4 minutes]

A Melting Pot of Strategies and Collaboration at the 2025 MDA Conference: Sharon Hesterlee, PhD

The chief research officer of the Muscular Dystrophy Association talked about what is to be expected at the 2025 MDA Conference, held March 16-19, in Dallas, Texas. [WATCH TIME: 5 minutes]

Using the DAAE Score to Advance Personalized Medicine for Multiple Sclerosis: Tom Fuchs, MD, PhD

The postdoctoral researcher at Amsterdam University Medical Center talked about the DAAE score 2.0 which offers an improved, validated clinical tool to predict the risk of transitioning to secondary progressive multiple sclerosis. [WATCH TIME: 5 minutes]

NeuroVoices: Wallace Brownlee, MBChB, PhD, FRACP, on Moving Toward a Unified, Biology-Driven Approach in the New Diagnostic Criteria for MS

The consultant neurologist at Queen's Square MS Center in London discussed the shift in the updates to the McDonald criteria for multiple sclerosis presented at ECTRIMS 2024.

Cutting-Edge, Multi-Arm OCTOPUS Trial Continues to Progress Well

Recruitment for the OCTOPUS trial, which explores alpha-lipoic acid and metformin in progressive multiple sclerosis (MS), is progressing well with nearly half of participants in stage 1 already randomized.

Key Challenges and Future Directions of Targeting mTOR for Epileptic Disorders: Ghayda Mirzaa, MD

The principal investigator at Seattle Children’s Research Institute described some of the ongoing questions that remain with developing therapeutics that target mTOR signaling pathway in pediatric epilepsy conditions. [WATCH TIME: 3 minutes]